Covalent Bruton tyrosine kinase inhibitors (BTKis) have improved CLL management, but discontinuation due to adverse events and disease progression remains a challenge. Sequential BCL2 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback